Home » IMMUNE RESPONSE REPORTS IR103 DATA
IMMUNE RESPONSE REPORTS IR103 DATA
The Immune Response Corporation has announced that preliminary Phase II study results of its second-generation HIV immunotherapy, IR103, demonstrated a positive safety profile and enhanced immunomodulatory effects over Remune, the company's first-generation immunotherapy.
IR103 differs from currently available antiretroviral drug therapies in that it is an immune-based therapy designed to replenish and enhance key immune cells that have been destroyed by the virus, thus allowing stimulation of an HIV-infected individual's immune system to fight the virus.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May